Securities Registration: Employee Benefit Plan (s-8)
August 17 2020 - 4:32PM
Edgar (US Regulatory)
Registration
No. 333 - _________
As
filed with the Securities and Exchange Commission on August 17, 2020
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
S-8
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
INTEC
PHARMA LTD.
(Exact
name of Registrant as specified in its charter)
Israel
|
|
Not
Applicable
|
(State or other jurisdiction
of
|
|
(IRS Employer
|
incorporation or
Organization)
|
|
Identification No.)
|
12
Hartom Street
Har
Hotzvim, Jerusalem 9777512, Israel
(+972)
(2) 586-4657
(Address
of principal executive offices)
Intec
Pharma Ltd. 2015 Equity Incentive Plan
(Full
title of the plan)
Intec
Pharma, Inc.
3
Columbus Circle - 15th Floor
New York, NY 10019
(646)
374-8050
(Name,
address, including zip code, and telephone number,
including
area code, of agent for service)
With
copies to:
Shachar
Hadar
Meitar
| Law Offices
16
Abba Hillel Silver Rd.
Ramat
Gan 52506, Israel
Tel: (+972)
(3) 610-3100
|
Gary
Emmanuel, Esq.
McDermott
Will & Emery LLP
340 Madison Avenue
New York, NY 10173
Tel:
(212) 547-5400
|
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated
filer ☐
|
Accelerated
filer ☒
|
Non-accelerated filer
|
Smaller reporting company
☒
|
|
Emerging growth company
☒
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
CALCULATION
OF REGISTRATION FEE
Title
of Securities to be Registered(1)
|
|
Amount
to be Registered
|
|
|
Proposed
Maximum Offering Price Per Security
|
|
|
Proposed
Maximum Aggregate Offering Price
|
|
|
Amount
of Registration Fee
|
|
Ordinary Shares, no par value
|
|
|
4,069,764
|
|
|
$
|
0.381
|
(2)
|
|
$
|
1,550,580
|
(2)
|
|
$
|
201.27
|
|
Ordinary Shares,
no par value
|
|
|
430,236
|
|
|
$
|
0.3075
|
(3)
|
|
$
|
132,298
|
(3)
|
|
$
|
17.17
|
|
Total
|
|
|
4,500,000
|
|
|
|
-
|
|
|
$
|
1,682,878
|
|
|
$
|
218.44
|
|
(1)
|
This
registration statement on Form S-8 (this “Registration Statement”) covers 4,500,000 ordinary shares, no par
value (the “Shares”) of Intec Pharma Ltd. (the “Registrant” or “Company”),
which may be issued under the Registrant’s 2015 Equity Incentive Plan (the “Plan”). In addition, pursuant
to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement
shall also cover any additional ordinary shares that become issuable under the Plan by reason of any share dividend, share split,
recapitalization or similar transaction effected without the receipt of consideration which results in an increase in the number
of the Company’s outstanding Ordinary Shares.
|
|
|
(2)
|
Calculated
pursuant to Rule 457(c) and (h) under the Securities Act. The proposed maximum offering price per ordinary share is $0.381, which
represents the average of the high and low prices per share of the Registrant’s ordinary shares as reported on the Nasdaq
Capital Market on August 14, 2020.
|
|
|
(3)
|
Determined
in accordance with Rule 457(g) under the Securities Act, based on the exercise price of $0.3075 per share at which the options
may be exercised.
|
EXPLANATORY
NOTE
This
Registration Statement registers an additional 4,500,000 Shares of the Company, which may be issued under the Plan. In accordance
with General Instruction E of Form S-8, the contents of the Company’s Registration Statements on Form S-8 (File Nos. 333-209700,
333-212801, 333-222217 and 333-227027) relating to the Plan, filed with the Securities and Exchange Commission (the “Commission”)
on February 25, 2016 and August 1, 2016, each as amended each by Post-Effective Amendments No. 1, filed with the Commission on
April 7, 2017, on December 21, 2017 and on August 27, 2018, are incorporated herein by reference except for Items 3 and 8 of the
Company's Registration Statement, which are included in this Registration Statement.
PART
I
INFORMATION
REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item
1. Plan Information*
Item
2. Registrant Information and Employee Plan Annual Information*
*
The documents containing the information specified in this Part I of Form S-8 (plan information and registrant information
and employee plan annual information) will be sent or given to employees as specified by Securities and Exchange Commission
Rule 428(b)(1). Such documents need not be filed with the Commission either as part of this Registration Statement or as
prospectuses or prospectus supplements pursuant to Rule 424. These documents and the documents incorporated by reference in
this Registration Statement pursuant to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that
meets the requirements of Section 10(a) of the Securities Act.
PART
II
INFORMATION
REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The
following documents, which have been filed with the Commission by the Company, are incorporated herein by reference into this
Registration Statement:
|
●
|
Our
Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 13, 2020;
|
|
|
|
|
●
|
our Quarterly Report
on Form 10-Q for the quarter ended on March 31, 2020 and June 30, 2020, filed with the SEC on May 11, 2020 and August 5, 2020, respectively;
|
|
|
|
|
●
|
our
Current Reports on Form 8-K (other than the information furnished pursuant to Item 2.02 or 7.01 thereof or related exhibits
furnished pursuant to Item 9.01 thereof) filed with the SEC on February 3, 2020, May 6, 2020, June 8, 2020,
July 17, 2020 and August 10, 2020; and
|
|
●
|
the description
of our ordinary shares contained in Item 1 of the Registration Statement on Form 8-A (File No. 001-37521), filed
with the SEC on July 28, 2015, including any amendment or report filed for the purpose of updating such description.
|
We
also incorporate by reference all future documents (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K)
we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, subsequent
to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement
which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold.
Any
statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated
by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that
a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also
is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement, except as to such
specific section of such statements as set forth therein.
Item
8. Exhibits
See
attached Exhibit Index.
SIGNATURES
Pursuant
to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Jerusalem, Israel on the 17th day of August, 2020.
|
INTEC PAHRMA LTD.
|
|
|
|
By:
|
/s/
Jeffrey A. Meckler
|
|
Name:
|
Jeffery A. Meckler
|
|
Title:
|
Chief Executive Officer and Vice Chairman
|
POWER
OF ATTORNEY
We,
the undersigned directors and/or officers of the Registrant, hereby severally constitute and appoint Jeffrey A. Meckler and Nir
Sassi, and each of them singly, our true and lawful attorneys, with full power to any of them, and to each of them singly, to
sign for us and in our names in the capacities indicated below the registration statement on Form S-8 filed herewith, and
any and all amendments to said registration statement, and any registration statement filed pursuant to Rule 462(b) under
the Securities Act, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith,
with the Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every
act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them
might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute
or substitutes, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant
to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities
indicated as of the 17th day of August, 2020.
Signature
|
|
Title
|
|
|
|
/s/ Dr.
John W. Kozarich
|
|
Chairman
of the Board of Directors
|
Dr.
John W. Kozarich
|
|
|
|
|
|
/s/ Jeffery
A. Meckler
|
|
Chief
Executive Officer and Vice Chairman (principal executive officer)
|
Jeffery
A. Meckler
|
|
|
|
|
|
/s/ Nir
Sassi
|
|
Chief
Financial Officer (principal financial and accounting officer)
|
Nir
Sassi
|
|
|
|
|
|
/s/ Hila
Karah
|
|
Director
|
Hila
Karah
|
|
|
|
|
|
/s/ Anthony
J. Maddaluna
|
|
Director
|
Anthony
J. Maddaluna
|
|
|
|
|
|
/s/ Dr.
Roger J. Pomerantz
|
|
Director
|
Dr.
Roger J. Pomerantz
|
|
|
|
|
|
/s/ William
B. Hayes
|
|
Director
|
William B.
Hayes
|
|
|
|
|
|
SIGNATURE
OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT
Pursuant
to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United
States of Intec Pharma Ltd. has signed this Registration Statement on this 17th day of August, 2020.
|
INTEC PHARMA, INC.
|
|
|
|
By:
|
/s/
Nir Sassi
|
|
Name:
|
Nir Sassi
|
|
Title:
|
Secretary
|
EXHIBIT
INDEX
5
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Apr 2023 to Apr 2024